MARKET WIRESeeking Alpha • 23h ago
Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First (NASDAQ:NBTX)Seeking Alpha report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
Why NBTX Stock dropped -10.39% Today — RQD Quant Desk Flash
$28.11 -10.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $27.53
Nanobiotix S.A. (NBTX) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.59B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NBTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NBTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Nanobiotix S.A. (NASDAQ: NBTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $28.11 (-10.39% 1D, market cap $1.59B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, NBTX ranks #275 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NBTX compare to URGN and RARE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBTX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, URGN (UroGen Pharma Ltd.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and RARE (Ultragenyx Pharmaceutical Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $1.59B). Among the 5-stock peer group, NBTX leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NBTX?
▼
For Nanobiotix S.A. (NBTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #275 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $27.53 (-2.06%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (49/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NBTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (49/100 Composite)
🔍 WHY NBTX SCORES 49/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL Trailing 12 Months: 1.1% FCF Margin ($44.6M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$21.49+12.3% Next Q
41
Q2 (-2Q)Grade D$24.14+43% Next Q
44
Q3 (-1Q)Grade D$34.53-18.6% Next Q
46
CurrentGrade D$28.11-5.4% Hist 90D α
49
Trajectory: D (41) → D (49)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NBTX Turnaround Squeeze
While NBTX currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.17) and Max Pain ($29.52) forces dealer call-delta covering toward $60.00.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NBTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NBTX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NBTX Stock dropped -10.39% Today — RQD Quant Desk Flash
Nanobiotix S.A. (NBTX) dropped -10.39% to $28.11, trading at 27% of its 52-week range ($17.42 – $57.14). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 27% of its 52-week range ($17.42 – $57.14) with RSI-14 at 53.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $28.11 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $44.6M annual free cash flow.
Live NBTX Headlines & Catalysts
MARKET WIREStock Titan • 1d ago
Nanobiotix (NBTX) had 54.7M votes eligible to be cast on Sept. 30, alongside 51M shares outstanding.Stock Titan report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Weekly Recap: Phase 1/1100 efficacy results and AMF voting-rights filingTradingView report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Nanobiotix (NBTX) Slips 1.03% to $21.08 as Shares Test Lower Support Zone - Flat Correctionhttps://www.siam.in/ report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
Nanobiotix (NBTX) Shares Gain 7.00% to $25.83, Pressing Toward $27.12 Resistance - Volatility Smilehttps://www.dars.gov.et/ report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A 24-person study of treatment-resistant melanoma reported median survival of 17.8 months.Stock Titan report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Four complete responses emerge in Nanobiotix (NBTX)'s 24-patient melanoma study.Stock Titan report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Share Gain - Short-Term Outlookhttps://www.dars.gov.et/ report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 1d ago
Kosmos Energy Posts Downbeat Q3 Results, Joins Once Upon A Farm And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionU.S. futures rose, but Kosmos Energy plunged 13.6% after missing Q3 earnings and sales estimates; other stocks also fell in premarket trading.
RISK WATCHYahoo • 7d ago
Nanobiotix (ENXTPA:NANO) Could Be 46% Undervalued As Melanoma Trial Results LandNanobiotix (ENXTPA:NANO) is back in focus after releasing updated Phase 1 data for JNJ-1900, or NBTXR3, in anti-PD-1-resistant advanced primary cutaneous melanoma treated with radiotherapy plus checkpoint inhibitors. The
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NBTX)
- ✓Walkthrough of NBTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NBTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.79%▼ DESCENDING CHANNEL
2026-11-03O $33.80H $33.80L $28.11C $28.11VOL 235.7K
RES: $33.34SUP: $18.24SMA50: $32.17SMA200: $33.96
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NBTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NBTX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NBTX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NBTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NBTX)
Health Care Rank #275 of 1015
⚔️ URGN vs NBTX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NBTX vs. URGN, RARE, CMPS, MLYS)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Nanobiotix S.A. (NBTX) ranks #275 by composite RQD confidence (49/100, grade D) and #292 by equity capitalization ($1.59B). Within this direct 5-issuer industry benchmark cohort, NBTX leads on earnings valuation at N/A trailing P/E, while MLYS leads on capital efficiency and profitability with -28.4% ROIC and — gross margin. NBTX currently leads its immediate peer cohort in composite quantitative strength at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NBTX
ACTIVE
Nanobiotix S.A. | D | 49/100 | — | — | — | -10.39% | $1.59B | Benchmark Subject |
| URGN UroGen Pharma Ltd. | E | 24/100 | — | 88.7% | -35.0% | +5.01% | $1.60B | /urgn-vs-nbtx → |
| RARE Ultragenyx Pharmaceutical Inc. | E | 23/100 | — | — | -35.0% | +1.24% | $1.59B | /rare-vs-nbtx → |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 40/100 | — | — | -35.0% | -27.31% | $1.60B | /cmps-vs-nbtx → |
| MLYS Mineralys Therapeutics Inc. | E | 33/100 | — | — | -28.4% | -14.47% | $1.61B | /mlys-vs-nbtx → |
2. NBTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTNanobiotix S.A. (NBTX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.59B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. NBTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NBTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Nanobiotix S.A. (NASDAQ: NBTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $28.11 (-10.39% 1D, market cap $1.59B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, NBTX ranks #275 in composite RQD confidence.
How does NBTX compare to URGN and RARE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NBTX carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, URGN (UroGen Pharma Ltd.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.60B) and RARE (Ultragenyx Pharmaceutical Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $1.59B). Among the 5-stock peer group, NBTX leads on earnings multiple (N/A) while MLYS leads on capital efficiency (-28.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NBTX?
For Nanobiotix S.A. (NBTX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #275 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NBTX trading relative to its 50-day, 200-day, and 52-week technical levels?
NBTX last traded at $28.11 (-10.39% on volume of 119,209 shares), positioning the stock -12.62% below its 50-day simple moving average ($32.17) and -17.23% below its 200-day simple moving average ($33.96). Across its 52-week range of $17.42 to $57.14, NBTX sits at the 26.9% percentile with a 14-day RSI of 53.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($24.60 to $31.62).
ROARABLE RATING BRIEF • RQD 49/100 (D)
✓ SEC XBRL & RQD VERIFIED
NBTX — Nanobiotix S.A.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Nanobiotix S.A. (NBTX) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $28.11 (-10.39% 1D, market capitalization $1.59B).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Nanobiotix S.A. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. — Its market capitalization is reported as $1.7B.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D • RQD 49/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $17.42 – $57.14 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The only sector context in the source is the classification of Health Care and Biotechnology: Pharmaceutical Preparations, with a beta of 1.0 per the market data. For a prospective investor, the principal second-order watch item is the Phase 3 timing and creditor-priority theme raised in the Seeking Alpha headline, but the source does not describe the underlying dependencies.
- Key Question #1: Can NBTX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $57.14 52-week high?
- Key Question #3: How sensitive is NBTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NBTX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Nanobiotix S.A. (NBTX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Seeking Alpha • 23h ago
Nanobiotix: The Phase 3 May Come Later, And Lenders Get Paid First (NASDAQ:NBTX) Seeking Alpha report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Nanobiotix (NBTX) had 54.7M votes eligible to be cast on Sept. 30, alongside 51M shares outstanding. Stock Titan report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Weekly Recap: Phase 1/1100 efficacy results and AMF voting-rights filing TradingView report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Nanobiotix (NBTX) Slips 1.03% to $21.08 as Shares Test Lower Support Zone - Flat Correction https://www.siam.in/ report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
Nanobiotix (NBTX) Shares Gain 7.00% to $25.83, Pressing Toward $27.12 Resistance - Volatility Smile https://www.dars.gov.et/ report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A 24-person study of treatment-resistant melanoma reported median survival of 17.8 months. Stock Titan report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Four complete responses emerge in Nanobiotix (NBTX)'s 24-patient melanoma study. Stock Titan report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
NBTX Q2 2026 Earnings: Wider-Than-Expected Loss Overshadows Modest Share Gain - Short-Term Outlook https://www.dars.gov.et/ report covering Nanobiotix S.A. (NBTX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NBTX Bull vs. Bear Conversation Board — What's Your Call at $28.11?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NBTX 🐻 33% BEARISH CONVICTION
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $37.64 (+20.0%)
📌 Pinned Debate Per the RQD rating, the forensic balance sheet scores 13/20 with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, the strongest pill
Long NBTX at $31.37 targeting $37.64. Per the RQD rating, the forensic balance sheet scores 13/20 with Altman Z 2.5, Piotroski F 6/9, and Debt/Equity 0.5, the strongest pillar in the rating.. Institutional whale score is 7/20 and the risk/reward vs. the $17.42 52-week low is skewed heavily in favor of bulls.
ArenaChamp_24 🐂 BULL
@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $26.98 (-14.0%)
Spot @ $31.37 Per the market data, ROIC is 0% and FCF yield is 0%, and P/E and EPS are unavailable, leaving no measured earnings or cash return behin
Fading this rally in NBTX at $31.37. Per the market data, ROIC is 0% and FCF yield is 0%, and P/E and EPS are unavailable, leaving no measured earnings or cash return behind the $33.8 price.. With a beta of 1.0 and the stock sitting at $31.37 (52-wk range $17.42–$57.14), the easy multiple expansion is already priced in.